Welcome to the IRadimed Corporation Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. And at the end of the call, we will conduct a question-and-answer session. As a reminder, this call is being recorded today, November 3, 2022 and contains time-sensitive information that is accurate only as of today. Earlier, IRadimed released its financial results for the third quarter of 2022. A copy of this press release announcing the company's earnings is available under the heading news on their website at iradimed.com. A press release copy was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live over the Internet on the company's website at iradimed.com and a replay of the call will be available on the website for the next 90 days. Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those focused on the future performance results, plans, and events and may include the company's expected future results. IRadimed reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the risk factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained for free from the SEC’s website at sec.gov. I would now like to turn the call over to Roger Susi, President and Chief Executive Officer of Iradimed Corporation. Mr. Susi, please go ahead.

Thank you operator. Good morning. And thank you for joining us on the call everyone. Today I am again having the pleasant task of reporting that Iradimed has had yet another excellent quarter of revenue and earnings growth as we reported in this morning's release. Q3, 2022 has been our top revenue quarter ever and the third in a string of our strongest growth quarters. Further, I'll interject here that the strong growing demand for our products remains intact, which gives us confidence in the coming quarters that we will also and gives you much more to be proud of there in the future. As reported in this morning's release, third quarter revenue was 13.4 million a 23% increase over the third quarter last year. GAAP diluted earnings per share were $0.27 or 35% above the third quarter 2021. I'm very pleased with these results and the hard efforts of our team. With three quarters behind us and growing at record levels we look forward to achieving our guidance for the year. Those supply risks are still very much a concern. The team has succeeded in finding ways to prevail, and we feel that measures put into place these past several months will continue to help mitigate supply risk. Our sales team continues to perform exceptionally well, increasingly driving customer demand for our products. The total Q3 bookings reached record levels again coming in higher than shipments for the quarter, thus boosting backlog yet again to an even more comfortable level. Additionally, strong backlog provides excellent visibility and it allows us to maneuver and reallocate resources as supply issues may arise. Sales growth was well balanced and strong for both the pump and the monitor product lines with an increasing number of the new FMD product shipping as well this…

Thank you, Roger and good morning everyone. As in the past our results are reported on a GAAP basis and a non-GAAP basis. You can find a description of our non-GAAP operating measures in this morning's earnings release and a reconciliation of these non-GAAP measures to the gap measure on the last page of today's release. As we reported earlier this morning, revenue in the third quarter of 2022 was 13.4 million, an increase of 23% compared to third quarter of 2021. Domestic sales increased 24.6% to 10.8 million and international sales increased 16.4% to 2.6 million. Overall domestic revenue accounted for 80.6% of total revenue for Q3, 2022 compared to 79.6% for Q3, 2021. Device revenue increased 32.2% to $9.4 million. This was driven by a 46% increase in monitor revenue as our sales team continued to execute and gain market share in the monitoring business. The average selling price of our MRI compatible IV infusion pump system during the third quarter of 2022 was approximately $30,000 compared to approximately $33,000 for the third quarter of 2021. This decrease relates to higher international unit sales and an unfavorable product sales mix, compared to the same period in 2021. The average selling price of our MRI compatible patient vital signs monitoring system during the third quarter of 2022 with approximately $46,000 compared to approximately $41,000 for the same period in 2021. This increase relates to higher domestic unit sales and price increases that we began implementing during the second half of 2021. Revenue from disposables and services increased 5.3% to 3.4 million for the third quarter of 2022 while our maintenance contracts were consistent at a $0.5 million for both periods. The gross margin was 78.6% for the 2022 quarter compared to 77.1% for the 2021 quarter. The increase in…